Open Medicine Foundation

The Open Medicine Foundation (OMF) is an American non-profit 501(c)(3) organization established in 2012. It funds and initiates groundbreaking research into complex chronic illnesses. It supports neuro-immune disease research with a focus on Chronic Fatigue Syndrome (CFS), Myalgic Encephalomyelitis (ME), Fibromyalgia (FMS), and Chronic Lyme Disease.

The OMF's current project is the End ME/CFS Project.

Many of those involved in OMF, including Executive Director Linda Tannenbaum, either have a neuro-immune disease or have a family member who has a neuro-immune disease.

OMF's strategy is to include highly recognized and accomplished scientists with expertise in body systems linked to neuro-immune diseases. The organization also has an extensive patient network as developed through email newsletter subscriptions.

ME/CFS Scientific Advisory Board
The advisory board is made up of world-renowned researchers:


 * Dr. Ronald Davis (Scientific Advisory Board Director, and father of Whitney Dafoe)
 * Paul Berg (cellular metabolism, Nobel laureate)
 * Mario Capecchi (genetics, Nobel laureate)
 * Mark Davis (immunology)
 * Craig Heller (exercise physiology)
 * Andreas Kogelnik (OMI founder)
 * Robert Naviaux (virology & cell biology, mitochondrial specialist)
 * Baldomero Olivera (neurobiology & pain)
 * Ronald Tompkins (trauma & metabolism)
 * James Watson (genetics, Nobel laureate)
 * Wenzhong Xiao (computational genomics)
 * David Bell (ME/CFS clinician. See Lyndonville outbreak)

Research Projects
The ME/CFS Severely Ill, Big Data Study was announced in May, 2015. The most severely ill ME/CFS patients are being studied to find a diagnostic bio-marker.

Advocacy
The OMF and the Davis-Dafoe Family held two screenings of Forgotten Plague. Dr. Davis spoke about ME/CFS and research after the screening.

Dr. Davis, along with colleagues, have written Open Letters in reference to research funds and the PACE trial.

Talks and interviews

 * Episode 79 - Linda Tannenbaum

Online Presence

 * Website
 * Facebook
 * Twitter
 * YouTube